XT
BCTX

XTX Topco’s Briacell Therapeutics BCTX Stock Holding History

XTX Topco’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-176
Closed -$32.8K – 2300
2024
Q3 		$32.8K Buy
176
+94
+115% +$10.6K ﹤0.01% 1766
2024
Q2 		$14.1K Buy
+82
New +$23.2K ﹤0.01% 1655
2023
Q2 		– Sell
-69
Closed -$77.4K – 1421
2023
Q1 		$77.4K Buy
+69
New +$71.5K 0.02% 1126
2022
Q3 		– Sell
-94
Closed -$82K – 1106
2022
Q2 		$82K Buy
+94
New +$92.9K 0.03% 689

Other funds holding BCTX

Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OBWG
Onyx Bridge Wealth Group Tarrytown, New York $1.11B AUM 24.65% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

XTX Topco's BCTX Position: Q4 2024 in Review

XTX Topco sold out of Briacell Therapeutics (BCTX) in Q4 2024, closing a stake of 176 shares — an estimated $32.8K sold.

XTX Topco first reported a position in BCTX in Q2 2022 and held it in 4 quarters. The position peaked at $82K in Q2 2022. 25 funds tracked by Wall St. Rank hold BCTX as of Q4 2024.

  • XTX Topco reported no remaining Briacell Therapeutics position as of Q4 2024 after selling out during the quarter.
  • XTX Topco sold 176 Briacell Therapeutics shares in Q4 2024, an estimated $32.8K.
  • XTX Topco first reported a position in Briacell Therapeutics in Q2 2022 and held it in 4 quarters.
  • XTX Topco's Briacell Therapeutics position peaked at $82K in Q2 2022.
  • 25 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q4 2024.

Based on XTX Topco's 13F filing for Q4 2024, filed 13 Feb 2025.